New study aims to boost safety of targeted radiation cancer treatment
NCT ID NCT07389512
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether having a pharmacist review all medications (including those from other doctors) can improve safety for cancer patients receiving targeted radionuclide therapy. The study will include 600 adults with thyroid cancer, metastatic prostate cancer, or neuroendocrine tumors. Researchers will compare the number of medication changes suggested by pharmacists when they do a full medication review versus when they only check medical records.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CGFL Dijon
NOT_YET_RECRUITINGDijon, 21000, France
-
Centre Hospitalier Universitaire de Lille
NOT_YET_RECRUITINGLille, France
-
Hospices Civils de Lyon
RECRUITINGBron, 69677, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A good Night's sleep: could a simple program ease Cancer's toll on rest?
- Chemo combo vs. radioactive drug: which tames aggressive prostate cancer?
- Genetic test may spare patients from unnecessary thyroid surgery
- Could sitting up make radiation therapy more comfortable?
- Can we predict dangerous side effects when combining radiation and immunotherapy?
- Family history as a shield: can culturally tailored guidance cut cancer risk?